Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Viral Vector Manufacturing Market From 2025 to 2029?

The market size of viral vector manufacturing has witnessed rapid expansion in the previous years. It is predicted to rise from $6.93 billion in 2024 and reach a value of $8.26 billion in 2025, with a compound annual growth rate (CAGR) of 19.1%. Various factors have attributed to the historic growth such as the expansion in the gene therapies pipeline, successful clinical trials and regulatory approvals, a higher level of investment in biopharmaceuticals, and a surge in the incidence of genetic disorders.

It’s anticipated that the viral vector manufacturing market will undergo substantial growth in the coming years, expanding to a size of $17.42 billion by 2029 with a compound annual growth rate (CAGR) of 20.5%. This growth during the forecast period is largely due to its increasing use in oncology, international collaborations on gene therapy research, the use of viral vectors in vaccine development, ongoing clinical trials, and commercialization. Some significant trends expected during this forecast period include technological advancements in vector production, the emergence of next-gen vectors, adherence to regulatory standards, cooperation and partnerships, and worldwide expansion of manufacturing facilities.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Elements Are Contributing To Growth In The Viral Vector Manufacturing Market?

The viral vector manufacturing market is poised for growth, primarily due to the rising incidences of cancer and infectious diseases. An infectious disease is caused by a virus or its toxic byproduct and spreads to a susceptible host through contact with an infected person, animal, or object. Cancer is a group of diseases characterized by uncontrollable growth and spread of abnormal cells in any body organ or tissue. Viral vectors are used to produce tumor antigens, proteins found on cancer cells, to stimulate the body’s immune response against cancer. They have been used in pre-clinical and clinical trials as vaccines against a variety of infectious diseases. The Australian Institute of Health and Welfare, a governmental agency based in Australia, reported a significant annual increase in cancer diagnoses in Australia, rising from 160,570 in 2022 to 164,694 in 2023. This rising trend underscores the increased cancer incidence in the country. Additionally, in August 2024, according to the UK Health Security Agency, a UK-based executive agency, 368 measles cases were reported in England in 2023, up nearly seven times from the 53 cases in 2022. The West Midlands and London accounted for 44% and 33% of these cases, respectively. Hence, the escalating incidences of cancer and infectious diseases are the primary driving factors propelling the growth of the viral vector manufacturing market.

Which Segments Are Detailed In The Global Viral Vector Manufacturing Market Report?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Which Emerging Trends And Strategic Shifts Are Shaping The Viral Vector Manufacturing Market?

One of the emerging trends in the unit-dose manufacturing market is product innovation. Key players in this market are creating novel products to keep their market position intact. For instance, in August 2024, Eli Lilly and Company, a healthcare company based in the US, has made available their Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials created specifically for self-paying patients with an on-label prescription. This was done to accommodate the increasing demands comprehensively. These vials are offered at a 50% discount, or even more, in comparison to the listed prices of other incretin (GLP-1) obesity treatments. This novel approach provides cost-effective access to a vast number of adult obesity patients, including those who do not qualify for the Zepbound savings card, those lacking employer-provided insurance, and those paying out-of-pocket without insurance.

Who Are The Key Contributors To Growth In The Viral Vector Manufacturing Market?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Region Is Projected To Lead The Viral Vector Manufacturing Market By 2025?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model